Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Daniel E Meyers"'
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5498-5515 (2024)
Since the initial US FDA approval of an immune checkpoint inhibitor (ICI) for the treatment of non-oncogene-driven non-small-cell lung cancer (NSCLC) nine years ago, this therapeutic strategy has been cemented as a crucial component of treatment for
Externí odkaz:
https://doaj.org/article/c6a25f9571974d2f9ffe6c77cea1e132
Autor:
Annalise G. Abbott, Daniel E. Meyers, Golpira Elmi-Assadzadeh, Igor Stukalin, Alessandro Marro, Shannon K. T. Puloski, Don G. Morris, Winson Y. Cheung, Michael J. Monument
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundBone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose of this study was to compare
Externí odkaz:
https://doaj.org/article/8e3e67f0686b45c6b44687246b392205
Autor:
Mehul Gupta, Igor Stukalin, Daniel E. Meyers, Daniel Y. C. Heng, Jose Monzon, Tina Cheng, Vishal Navani
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe association between objective imaging response and first line immune checkpoint inhibitor (ICI) therapy regimes in advanced melanoma remains uncharacterized in routine practice.MethodsWe conducted a multi-center retrospective cohort ana
Externí odkaz:
https://doaj.org/article/3a7a0cf228e44e9382aeb927341c82e3
Autor:
Kristina Jenei, Daniel E Meyers
Publikováno v:
BMJ Open, Vol 13, Iss 10 (2023)
Objective To examine characteristics of clinician input to the pan-Canadian Oncology Drug Review (pCODR) for cancer drug funding recommendations from 2016 to 2020.Design, setting and participants Descriptive, cross-sectional study including 62 reimbu
Externí odkaz:
https://doaj.org/article/a6e14666771b4f44bb1863cdfb5c2d21
Autor:
Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, Michael Sander, Philip Q. Ding, Daniel E. Meyers, Daniel Heng, Winson Y. Cheung, Tina Cheng
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7695-7704 (2022)
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elus
Externí odkaz:
https://doaj.org/article/1f5f9e1739c3404695cccba5ce955721
Autor:
Daniel E. Meyers, MD, MSc, Meghann Pasternak, MD, MSc, Samantha Dolter, MD, Heidi A.I. Grosjean, MD, Chloe A. Lim, MD, Igor Stukalin, MD, Siddhartha Goutam, MD, Vishal Navani, M.B.B.S., MRCP, Daniel Y.C. Heng, MD, MPH, Winson Y. Cheung, MD, PhD, Don G. Morris, MD, PhD, Aliyah Pabani, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100482- (2023)
Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology Group performance stat
Externí odkaz:
https://doaj.org/article/60af4c1049ba410eb0ed27eb16724e8a
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 4542-4551 (2021)
Malignant pleural mesothelioma is a rare and aggressive malignancy arising from mesothelial cells that line the serous membranes of the body. Cytotoxic chemotherapy has been a mainstay of therapy, resulting in a modest improvement in overall survival
Externí odkaz:
https://doaj.org/article/0e809a0640d94465843efc77da7bb2b8
Autor:
Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4213-4222 (2021)
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice
Externí odkaz:
https://doaj.org/article/ef1a3db40d2d4a92a300be45448be0e8
Autor:
Michael S. Sander, Igor Stukalin, Isabelle A. Vallerand, Siddhartha Goutam, Benjamin W. Ewanchuk, Daniel E. Meyers, Aliyah Pabani, Don G. Morris, Daniel Y. C. Heng, Tina Cheng
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2618-2626 (2021)
Abstract Background Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. Currently, prognostic biomarkers are lacking to
Externí odkaz:
https://doaj.org/article/912792318bd545cba1e0cd7fc036db6d
Autor:
Steven M. Yip, Daniel E. Meyers, Jeff Sisler, Keith Wycliffe-Jones, Edward Kucharski, Christine Elser, Claire Temple-Oberle, Silvana Spadafora, Paris-Ann Ingledew, Meredith Giuliani, Sara Kuruvilla, Nureen Sumar, Vincent C. Tam
Publikováno v:
BMC Medical Education, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background This study aimed to determine the current state of oncology education in Canadian family medicine postgraduate medical education programs (FM PGME) and examine opinions regarding optimal oncology education in these programs. Metho
Externí odkaz:
https://doaj.org/article/cae1dfba240343e4b985f2e250ee379f